Panitumumab IRDye 800

DRUG2 trials

Sponsors

Eben Rosenthal, Vanderbilt-Ingram Cancer Center

Conditions

HNSCCHNSCC,Larynx, Pharynx and Oral CavityHead and Neck CancerSCC - Squamous Cell Carcinoma

Phase 1

Panitumumab IRDye800 Optical Imaging Study

CompletedNCT02415881

Eben RosenthalHead and Neck Cancer

Start: 2016-08-31End: 2021-09-21Updated: 2021-09-24

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

RecruitingNCT06819228

Vanderbilt-Ingram Cancer CenterHNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma

Start: 2025-04-17End: 2029-03-01Target: 70Updated: 2026-08-03

Related Papers

Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer

Journal of Nuclear Medicine2021-09-1620 citations

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Nature Communications2020-11-0999 citations

Effect of Formalin Fixation for Near-Infrared Fluorescence Imaging with an Antibody-Dye Conjugate in Head and Neck Cancer Patients.

2020-10-196 citations

Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.

2019-08-1214 citations

The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer

Journal of Nuclear Medicine2019-02-07108 citations